Ranbaxy files consent decree with US court

Image
Press Trust of India New Delhi
Last Updated : Jan 20 2013 | 2:56 AM IST

Drug firm Ranbaxy Laboratories today said it has filed a consent decree with a US court as part of its settlement with the American authorities regarding a ban on certain manufacturing plants operated by the company in India.

The Gurgaon-based company today announced that the consent decree with the US Food and Drug Administration that was signed on December 20, 2011, has been filed with the United States District Court for the District of Maryland.

In 2008, the USFDA had banned 30 generic drugs produced by Ranbaxy at its Dewas (Madhya Pradesh) and Paonta Sahib and Batamandi unit in Himachal Pradesh, citing gross violation of approved manufacturing norms.

In the same year, the US Department of Justice had moved a motion against the company in a local court alleging forgery of documents and fraudulent practice.

"Under the terms of the consent decree, which is subject to approval by this court, Ranbaxy has committed to further strengthen procedures and policies to ensure data integrity and to comply with current good manufacturing practices," it added.

Commenting on the development, Ranbaxy CEO and Managing Director Arun Sawhney said: "Today's announcement is the next step in the process of finalising our agreement with the FDA to resolve this legacy issue."

"We are pleased with the progress we have made in upgrading and enhancing the quality of our business and manufacturing processes and remain committed to ensuring that all of our facilities and products meet the high standards that patients, prescribers and the public have come to expect from Ranbaxy," Sawhney added.

Last year, Ranbaxy signed a consent decree with the USFDA to lift the ban on import of drugs from certain manufacturing plants operated by the firm. It had also announced that it has set aside a provision of $500 million to settle its case with the US Department of Justice.

A consent decree is a settlement of a lawsuit or criminal case in which a person or company agrees to take specific actions without admitting fault or guilt for the situation that led to the lawsuit.

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Jan 26 2012 | 2:26 PM IST

Next Story